상세 보기
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
- Vink, Peter;
- Ramon Torrell, Josep Maria;
- Sanchez Fructuoso, Ana;
- Kim, Sung-Joo;
- Kim, Sang-Il;
- 외 37명
WEB OF SCIENCE
177SCOPUS
207초록
Background. The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients >= 18 years of age receiving daily immunosuppressive therapy. Methods. In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1-2 months (M) apart 4-18M posttransplant. Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates were assessed at 1M post-dose 1, and 1M and 12M post-dose 2. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Solicited general symptoms and unsolicited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential immune-mediated diseases (pIMDs) were recorded up to 12M post-dose 2. Results. Two hundred sixty-four participants (RZV: 132; placebo: 132) were enrolled between March 2014 and April 2017. gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across postvaccination time points and persisted above prevaccination baseline 12M post-dose 2. Local AEs were reported more frequently by RZV than placebo recipients. Overall occurrences of renal function changes, rejections, unsolicited AEs, serious AEs, and pIMDs were similar between groups. Conclusions. RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M postvaccination. No safety concerns arose.
키워드
- 제목
- Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
- 저자
- Vink, Peter; Ramon Torrell, Josep Maria; Sanchez Fructuoso, Ana; Kim, Sung-Joo; Kim, Sang-Il; Zaltzman, Jeff; Ortiz, Fernanda; Campistol Plana, Josep Maria; Fernandez Rodriguez, Ana Maria; Rebollo Rodrigo, Henar; Campins Marti, Magda; Perez, Rafael; Gonzalez Roncero, Francisco Manuel; Kumar, Deepali; Chiang, Yang-Jen; Doucette, Karen; Pipeleers, Lissa; Aguera Morales, Maria Luisa; Luisa Rodriguez-Ferrero, Maria; Secchi, Antonio; McNeil, Shelly A.; Campora, Laura; Di Paolo, Emmanuel; El Idrissi, Mohamed; Lopez-Fauqued, Marta; Salaun, Bruno; Heineman, Thomas C.; Oostvogels, Lidia; Rossana, Caldara; Mario, Carmellini; Yen-Ta, Chen; Giacomo, Garibotto; Esther, Gonzalez Montes; Nada, Kanaan; Dirk, Kuypers; Cheng-Chia, Lin; Umberto, Maggiore; Pavel, Navratil; Arjan, Van der Tol; Ignacio, Villate Navarro Jose; Bice, Virgilio; Ming-Ju, Wu
- 발행일
- 2020-01-15
- 유형
- Article
- 권
- 70
- 호
- 2
- 페이지
- 181 ~ 190
- 언어
- ENG
- 출판사
- University of Chicago Press
- 발행국가
- 미국
- 분량
- 10 페이지
- ISSN
- E 1537-6591
P 1058-4838